CGRP antagonists are a new class of drugs designed to prevent migraine headaches by targeting a key molecule involved in pain transmission. Calcitonin gene-related peptide (CGRP) monoclonal antibodies ...

Washington, DC — New phase 2 data on the investigational calcitonin gene-related peptide (CGRP) monoclonal antibodies show significant efficacy in preventing migraine attacks with no major safety ...

Aiming to break into a three-way battle among large drugmakers in the brand-new CGRP migraine class, tiny Biohaven Pharmaceutical has released detailed data for its own candidate, which one group of ...

Hayley Gudgin of Sammamish, Wash., got her first migraine in 1991 when she was a 19-year-old nursing student. “I was convinced I was having a brain hemorrhage,” she says. “There was no way anything ...

Adjunctive preventive therapy with a calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) medication is safe and effective in patients with chronic migraine who have only achieved a partial ...

Teva Pharmaceutical Industries Ltd. TEVA announced that its anti-calcitonin gene-related peptide (“CGRP”) injection, Ajovy, was granted marketing approval by the European Commission for prophylaxis of ...

Dublin, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The "Global CGRP Inhibitor Market (2023 Edition): Analysis By Treatment (Preventive, Acute), Route of Administration (Oral, Nasal, Intravenous), By End-User, ...

Health Canada approves PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 ...